biostudies-literatureUnknown27 Suppl 4Zargar AHZydus Healthcare LimitedIn India, the increasing prevalence of diabetes and obesity poses a significant threat towards a surge in the incidence of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD). Concomitant with the evolving guidelines, there is a need to direct and spread awareness among practicing diabetologists to identify and screen high-risk individuals for MASLD for timely management. Its asymptomatic nature and the evolving guidelines on diagnosis have hindered the precise estimates of MASLD in the high-risk group of individuals in a clinical setting. Therefore, an expert panel of diabetologists from India convened to review, discuss and document the approach towards screening, diagnosis and management of MASLD. Serum biomarkersDiabetes, obesity & metabolism3-20https://www.ebi.ac.uk/biostudies/studies/S-EPMC12150358biostudies-literatureManagement of metabolic dysfunction-associated steatotic liver disease (MASLD)-An expert consensus statement from Indian diabetologists' perspective.PMC12150358Majumdar ASanyal DDas SSaboo BDMehrotra RNZargar AHMaheshwari ASeshadri KGMohan VBhattacharyya ADasgupta AAgarwal SCGoswami SJoshi SRShaikh SSSahay RKKapoor NDeshpande NRKant STalwalkar PGGhosh SSethi BKLakhani OJShukla RKalra PPanikar VKPhatak SRG SBhansali AAravind SRfalseManagement of metabolic dysfunction-associated steatotic liver disease (MASLD)-An expert consensus statement from Indian diabetologists' perspective.In India, the increasing prevalence of diabetes and obesity poses a significant threat towards a surge in the incidence of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD). Concomitant with the evolving guidelines, there is a need to direct and spread awareness among practicing diabetologists to identify and screen high-risk individuals for MASLD for timely management. Its asymptomatic nature and the evolving guidelines on diagnosis have hindered the precise estimates of MASLD in the high-risk group of individuals in a clinical setting. Therefore, an expert panel of diabetologists from India convened to review, discuss and document the approach towards screening, diagnosis and management of MASLD. Serum biomarkers2025-01-01T00:00:00Z2025 Jun2026-04-08T14:51:08.479Z2026-04-08T03:51:46.718ZS-EPMC121503584045753210.1111/dom.16496